Literature DB >> 17350598

Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers.

Hiroo Nakajima1, Koichi Sakaguchi, Ikuya Fujiwara, Mitsuhiko Mizuta, Mie Tsuruga, Junji Magae, Naruhiko Mizuta.   

Abstract

A survival kinase, Akt, is a downstream factor in the phosphatidylinositide-3'-kinase-dependent pathway, which mediates many biological responses including glucose uptake, protein synthesis and the regulation of proliferation and apoptosis, which is assumed to contribute to acquisition of malignant properties of human cancers. Here we find that an anti-tumor antibiotic, tetrocarcin A, directly induces apoptosis of human breast cancer cells. The apoptosis is accompanied by the activation of a proteolytic cascade of caspases including caspase-3 and -9, and concomitantly decreases phosphorylation of Akt, PDK1, and PTEN, a tumor suppressor that regulates the activity of Akt through the dephosphorylation of polyphosphoinositides. Tetrocarcin A affected neither expression of Akt, PDK1, or PTEN, nor did it affect the expression of Bcl family members including Bcl-2, Bcl-X(L), and Bax. These results suggest that tetrocarcin A could be a potent chemotherapeutic agent for human breast cancer targeting the phosphatidylinositide-3'-kinase/Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350598     DOI: 10.1016/j.bbrc.2007.02.136

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Authors:  Nancy Lynn Booth; Thomas J Sayers; Alan D Brooks; Cheryl L Thomas; Kristen Jacobsen; Ekaterina I Goncharova; James B McMahon; Curtis J Henrich
Journal:  Cancer Immunol Immunother       Date:  2008-12-17       Impact factor: 6.968

2.  Identification of compounds by high-content screening that induce cytoplasmic to nuclear localization of a fluorescent estrogen receptor α chimera and exhibit agonist or antagonist activity in vitro.

Authors:  Angie B Dull; Anuja A George; Ekaterina I Goncharova; Jason R Evans; Antony Wamiru; Laura K Cartner; Gordon L Hager; James B McMahon
Journal:  J Biomol Screen       Date:  2013-09-19

Review 3.  Modulating splicing with small molecular inhibitors of the spliceosome.

Authors:  Kerstin A Effenberger; Veronica K Urabe; Melissa S Jurica
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-07-21       Impact factor: 9.957

4.  Cloning and characterization of the tetrocarcin A gene cluster from Micromonospora chalcea NRRL 11289 reveals a highly conserved strategy for tetronate biosynthesis in spirotetronate antibiotics.

Authors:  Jie Fang; Yiping Zhang; Lijuan Huang; Xinying Jia; Qi Zhang; Xu Zhang; Gongli Tang; Wen Liu
Journal:  J Bacteriol       Date:  2008-06-27       Impact factor: 3.490

5.  A high-throughput splicing assay identifies new classes of inhibitors of human and yeast spliceosomes.

Authors:  Kerstin A Effenberger; Rhonda J Perriman; Walter M Bray; R Scott Lokey; Manuel Ares; Melissa S Jurica
Journal:  J Biomol Screen       Date:  2013-06-14

6.  Effects of indomethacin on expression of PTEN tumour suppressor in human cancers.

Authors:  Imran Haruna Abdulkareem; Maria Blair
Journal:  Niger Med J       Date:  2013-03

7.  Phosphatase and tensin homologue deleted on chromosome 10.

Authors:  Imran Haruna Abdulkareem; Maria Blair
Journal:  Niger Med J       Date:  2013-03

Review 8.  Spirotetronate polyketides as leads in drug discovery.

Authors:  Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  J Nat Prod       Date:  2014-12-01       Impact factor: 4.050

9.  Biomedical techniques in translational studies: The journey so far.

Authors:  Imran Haruna Abdulkareem
Journal:  Niger Med J       Date:  2014-03

10.  PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.

Authors:  Ana Silva; J Andrés Yunes; Bruno A Cardoso; Leila R Martins; Patrícia Y Jotta; Miguel Abecasis; Alexandre E Nowill; Nick R Leslie; Angelo A Cardoso; Joao T Barata
Journal:  J Clin Invest       Date:  2008-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.